iSpecimen announces new suppliers, strengthens biospecimen offering

iSpecimen announced the addition of several new suppliers, expanded relationships with existing suppliers and new offerings to increase access to critically important biospecimens for advancing biomedical research in oncology. The expansion of the provider network offers researchers access to specimens from cancer patients in different treatment stages, with specific biomarkers and mutations, across many specimen formats, including various tissue types and biofluid formats. “Recognizing the fact that oncology research drives over 50 percent of the global demand for human biospecimens, we have been working diligently to significantly expand the iSpecimen Marketplace by increasing access to highly-sought-after oncology biospecimens. These specimens will be immediately available from inventory or prospectively from target patient populations across our global network of suppliers,” said Tracy Curley, iSpecimen’s CEO. “What’s more, researchers will now have access to fusion mutations and pre-screened DNA/RNA mutation characterized tumor tissue, meeting the specific demands of their research with enhanced precision and depth.”